BARRECA, Marilia
BARRECA, Marilia
Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche
[1,2]OXAZOLE DERIVATIVES: SYNTHESIS AND BIOLOGICAL EVALUATION AGAINST MULTIPLE MALIGNANT CELL TYPES
2021-05-04
An overview on anti-tubulin agents for the treatment of lymphoma patients
2020-01-01 Barreca M.; Stathis A.; Barraja P.; Bertoni F.
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
2022-12-01 Barreca M.; Lang N.; Tarantelli C.; Spriano F.; Barraja P.; Bertoni F.
Current development of CFTR potentiators in the last decade
2020-01-01 Spano' V.; Venturini A.; Genovese M.; Barreca M.; Raimondi M.V.; Montalbano A.; Galietta L.J.V.; Barraja P.
Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas
2022-12-05 Barreca M.; Spano' V.; Rocca R.; Bivacqua R.; Abel A.-C.; Maruca A.; Montalbano A.; Raimondi M.V.; Tarantelli C.; Gaudio E.; Cascione L.; Rinaldi A.; Bai R.; Steinmetz M.O.; Prota A.E.; Alcaro S.; Hamel E.; Bertoni F.; Barraja P.
Evaluation of [1,2]oxazolo[5,4-e]isoindoles in lymphoma cells
2020-01-01 Barreca M.; Spanò Virginia; Raimondi M.V.; Montalbano A.; Bai R.; Gaudio E.; Alcaro S.; Hamel E.; Bertoni Francesco; Barraja P.
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
2021-01-01 Spano' V.; Barreca M.; Cilibrasi V.; Genovese M.; Renda M.; Montalbano A.; Galietta L.J.V.; Barraja P.
GPCR Inhibition in Treating Lymphoma
2022-02-15 Barreca M.; Spano' V.; Raimondi M.V.; Bivacqua R.; Giuffrida S.; Montalbano A.; Cavalli A.; Bertoni F.; Barraja P.
Insight into non-nucleoside triazole-based systems as viral polymerases inhibitors
2023-03-05 Bivacqua R.; Barreca M.; Spano' V.; Raimondi M.V.; Romeo I.; Alcaro S.; Andrei G.; Barraja P.; Montalbano A.
Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors
2021-02-15 Spano' V.; Barreca M.; Rocca R.; Bortolozzi R.; Bai R.; Carbone A.; Raimondi M.V.; Palumbo Piccionello A.; Montalbano A.; Alcaro S.; Hamel E.; Viola G.; Barraja P.
Insight on pyrimido[5,4-g]indolizine and pyrimido[4,5-c]pyrrolo[1,2-a]azepine systems as promising photosensitizers on malignant cells
2022-07-05 Barreca M.; Ingarra A.M.; Raimondi M.V.; Spano' V.; De Franco M.; Menilli L.; Gandin V.; Miolo G.; Barraja P.; Montalbano A.
Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes
2020-01-01 Barreca M.; Spano' V; Montalbano A.; Cueto M.; Diaz Marrero A.R.; Deniz I.; Erdogan A.; Lukic Bilela L.; Moulin C.; Taffin-de-Givenchy E.; Spriano F.; Perale G.; Mehiri M.; Rotter A.; P Thomas O.; Barraja P.; Gaudencio S.P.; Bertoni F.
New tricyclic systems as photosensitizers towards triple negative breast cancer cells
2022-11-18 Barreca M.; Ingarra A.M.; Raimondi M.V.; Spano' V.; Palumbo Piccionello A.; De Franco M.; Menilli L.; Gandin V.; Miolo G.; Barraja P.; Montalbano A.
Novel insights on [1,2]oxazolo[5,4‐e]isoindoles on multidrug resistant acute myeloid leukemia cell line
2022-01-01 Manuela Labbozzetta; Marilia Barreca; Virginia Spano'; Maria Valeria Raimondi; Paola Poma; Monica Notarbartolo; Paola Barraja; Alessandra Montalbano
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma
2022-08-01 Spriano, Filippo; Sartori, Giulio; Tarantelli, Chiara; Barreca, Marilia; Golino, Gaetanina; Rinaldi, Andrea; Napoli, Sara; Mascia, Michele; Scalise, Lorenzo; Arribas, Alberto J; Cascione, Luciano; Zucca, Emanuele; Stathis, Anastasios; Gaudio, Eugenio; Bertoni, Francesco
Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
2020-01-01 Spano' V.; Rocca R.; Barreca M.; Giallombardo D.; Montalbano A.; Carbone A.; Raimondi M.V.; Gaudio E.; Bortolozzi R.; Bai R.; Tassone P.; Alcaro S.; Hamel E.; Viola G.; Bertoni F.; Barraja P.
Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity
2021-07-01 Barreca M.; Spano' V.; Raimondi M.V.; Tarantelli C.; Spriano F.; Bertoni F.; Barraja P.; Montalbano A.
Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models
2020-01-01 Spriano F.; Barreca M.; Miguel-Gordo M.; O'Brien S.; Arribas A.J.; Jennings L.; Thomas O.; Bertoni F.
Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
2020-01-01 A. Arribas, S. Napoli, L. Cascione, E. Gaudio, R. Bordone-Pittau, M. Barreca, G. Sartori, T. Chiara, F. Spriano, A. Rinaldi, A. Stathis, G. Stussi, D. Rossi, Z. Emanuele, F. Bertoni
Synthesis of 2H-Imidazo[2′,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations
2022-05-05 Cilibrasi V.; Spano' V.; Bortolozzi R.; Barreca M.; Raimondi M.V.; Rocca R.; Maruca A.; Montalbano A.; Alcaro S.; Ronca R.; Viola G.; Barraja P.
| Data di pubblicazione | Titolo | Autori | Tipologia | Autore(i) | File |
|---|---|---|---|---|---|
| 4-mag-2021 | [1,2]OXAZOLE DERIVATIVES: SYNTHESIS AND BIOLOGICAL EVALUATION AGAINST MULTIPLE MALIGNANT CELL TYPES | BARRECA, Marilia | 04 - Tesi di dottorato::4.2 Tesi di dottorato | - | |
| 1-gen-2020 | An overview on anti-tubulin agents for the treatment of lymphoma patients | Barreca M.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Barreca M.; Stathis A.; Barraja P.; Bertoni F. | |
| 1-dic-2022 | Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences | Barreca M.Barraja P. + | 01 - Contributo in rivista::1.09 Review essay (rassegna critica) | Barreca M.; Lang N.; Tarantelli C.; Spriano F.; Barraja P.; Bertoni F. | |
| 1-gen-2020 | Current development of CFTR potentiators in the last decade | Spano' V.Barreca M.Raimondi M. V.Montalbano A.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Spano' V.; Venturini A.; Genovese M.; Barreca M.; Raimondi M.V.; Montalbano A.; Galietta L.J.V.; Barraja P. | |
| 5-dic-2022 | Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: Further chemical modifications and potential therapeutic effects against lymphomas | Barreca M.Spano' V.Bivacqua R.Montalbano A.Raimondi M. V.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Barreca M.; Spano' V.; Rocca R.; Bivacqua R.; Abel A.-C.; Maruca A.; Montalbano A.; Raimondi M.V.; Tarantelli C.; Gaudio E.; Cascione L.; Rinaldi A.; Bai R.; Steinmetz M.O.; Prota A.E.; Alcaro S.; Hamel E.; Bertoni F.; Barraja P. | |
| 1-gen-2020 | Evaluation of [1,2]oxazolo[5,4-e]isoindoles in lymphoma cells | Barreca M.Spanò VirginiaRaimondi M. V.Montalbano A.Barraja P. + | 01 - Contributo in rivista::1.08 Poster pubblicato in rivista | Barreca M.; Spanò Virginia; Raimondi M.V.; Montalbano A.; Bai R.; Gaudio E.; Alcaro S.; Hamel E.; Bertoni Francesco; Barraja P. | |
| 1-gen-2021 | Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein | Spano' V.Barreca M.Montalbano A.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Spano' V.; Barreca M.; Cilibrasi V.; Genovese M.; Renda M.; Montalbano A.; Galietta L.J.V.; Barraja P. | |
| 15-feb-2022 | GPCR Inhibition in Treating Lymphoma | Barreca M.Spano' V.Raimondi M. V.Bivacqua R.Giuffrida S.Montalbano A.Barraja P. + | 01 - Contributo in rivista::1.09 Review essay (rassegna critica) | Barreca M.; Spano' V.; Raimondi M.V.; Bivacqua R.; Giuffrida S.; Montalbano A.; Cavalli A.; Bertoni F.; Barraja P. | |
| 5-mar-2023 | Insight into non-nucleoside triazole-based systems as viral polymerases inhibitors | Bivacqua R.Barreca M.Spano' V.Raimondi M. V.Barraja P.Montalbano A. + | 01 - Contributo in rivista::1.09 Review essay (rassegna critica) | Bivacqua R.; Barreca M.; Spano' V.; Raimondi M.V.; Romeo I.; Alcaro S.; Andrei G.; Barraja P.; Montalbano A. | |
| 15-feb-2021 | Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors | Spano' V.Barreca M.Carbone A.Raimondi M. V.Palumbo Piccionello A.Montalbano A.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Spano' V.; Barreca M.; Rocca R.; Bortolozzi R.; Bai R.; Carbone A.; Raimondi M.V.; Palumbo Piccionello A.; Montalbano A.; Alcaro S.; Hamel E.; Viola G.; Barraja P. | |
| 5-lug-2022 | Insight on pyrimido[5,4-g]indolizine and pyrimido[4,5-c]pyrrolo[1,2-a]azepine systems as promising photosensitizers on malignant cells | Barreca M.Ingarra A. M.Raimondi M. V.Spano' V.Barraja P.Montalbano A. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Barreca M.; Ingarra A.M.; Raimondi M.V.; Spano' V.; De Franco M.; Menilli L.; Gandin V.; Miolo G.; Barraja P.; Montalbano A. | |
| 1-gen-2020 | Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes | Barreca M.Spano' VMontalbano A.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Barreca M.; Spano' V; Montalbano A.; Cueto M.; Diaz Marrero A.R.; Deniz I.; Erdogan A.; Lukic Bilela L.; Moulin C.; Taffin-de-Givenchy E.; Spriano F.; Perale G.; Mehiri M.; Rotter A.; P Thomas O.; Barraja P.; Gaudencio S.P.; Bertoni F. | |
| 18-nov-2022 | New tricyclic systems as photosensitizers towards triple negative breast cancer cells | Barreca M.Ingarra A. M.Raimondi M. V.Spano' V.Palumbo Piccionello A.Barraja P.Montalbano A. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Barreca M.; Ingarra A.M.; Raimondi M.V.; Spano' V.; Palumbo Piccionello A.; De Franco M.; Menilli L.; Gandin V.; Miolo G.; Barraja P.; Montalbano A. | |
| 1-gen-2022 | Novel insights on [1,2]oxazolo[5,4‐e]isoindoles on multidrug resistant acute myeloid leukemia cell line | Manuela LabbozzettaMarilia BarrecaVirginia Spano'Maria Valeria RaimondiPaola PomaMonica NotarbartoloPaola BarrajaAlessandra Montalbano | 01 - Contributo in rivista::1.01 Articolo in rivista | Manuela Labbozzetta; Marilia Barreca; Virginia Spano'; Maria Valeria Raimondi; Paola Poma; Monica Notarbartolo; Paola Barraja; Alessandra Montalbano | |
| 1-ago-2022 | Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma | Barreca, Marilia + | 01 - Contributo in rivista::1.01 Articolo in rivista | Spriano, Filippo; Sartori, Giulio; Tarantelli, Chiara; Barreca, Marilia; Golino, Gaetanina; Rinaldi, Andrea; Napoli, Sara; Mascia, Michele; Scalise, Lorenzo; Arribas, Alberto J; Cascione, Luciano; Zucca, Emanuele; Stathis, Anastasios; Gaudio, Eugenio; Bertoni, Francesco | |
| 1-gen-2020 | Pyrrolo[2',3':3,4]cyclohepta[1,2-d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types | Spano' V.Barreca M.Montalbano A.Raimondi M. V.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Spano' V.; Rocca R.; Barreca M.; Giallombardo D.; Montalbano A.; Carbone A.; Raimondi M.V.; Gaudio E.; Bortolozzi R.; Bai R.; Tassone P.; Alcaro S.; Hamel E.; Viola G.; Bertoni F.; Barraja P. | |
| 1-lug-2021 | Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity | Barreca M.Spano' V.Raimondi M. V.Barraja P.Montalbano A. + | 01 - Contributo in rivista::1.09 Review essay (rassegna critica) | Barreca M.; Spano' V.; Raimondi M.V.; Tarantelli C.; Spriano F.; Bertoni F.; Barraja P.; Montalbano A. | |
| 1-gen-2020 | Screening of fractions from marine sponges and other invertebrates to identify new lead compounds with anti-tumor activity in lymphoma models | Barreca M. + | 01 - Contributo in rivista::1.05 Abstract in atti di convegno pubblicato in rivista | Spriano F.; Barreca M.; Miguel-Gordo M.; O'Brien S.; Arribas A.J.; Jennings L.; Thomas O.; Bertoni F. | |
| 1-gen-2020 | Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma | M. Barreca + | 01 - Contributo in rivista::1.05 Abstract in atti di convegno pubblicato in rivista | A. Arribas, S. Napoli, L. Cascione, E. Gaudio, R. Bordone-Pittau, M. Barreca, G. Sartori, T. Chiara, F. Spriano, A. Rinaldi, A. Stathis, G. Stussi, D. Rossi, Z. Emanuele, F. Bertoni | |
| 5-mag-2022 | Synthesis of 2H-Imidazo[2′,1':2,3] [1,3]thiazolo[4,5-e]isoindol-8-yl-phenylureas with promising therapeutic features for the treatment of acute myeloid leukemia (AML) with FLT3/ITD mutations | Spano' V.Barreca M.Raimondi M. V.Montalbano A.Barraja P. + | 01 - Contributo in rivista::1.01 Articolo in rivista | Cilibrasi V.; Spano' V.; Bortolozzi R.; Barreca M.; Raimondi M.V.; Rocca R.; Maruca A.; Montalbano A.; Alcaro S.; Ronca R.; Viola G.; Barraja P. |